GleamWall
中文EN

RAPH Raphael Pharmaceutical Inc.

Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1415397 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY33.4%
TTM EPS YoY-37.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-5,297.3%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets27,028.6%
Debt / equity—
Current ratio0.00x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.02x
Accruals ratio-5,216.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$631,000$776,000
SG&A expense$614,000$733,000
Operating income-$1.25M-$1.51M
Net income-$1.28M-$1.52M
EPS (basic)0.070.08
EPS (diluted)0.070.08
Weighted avg. shares (diluted)19.55M18.67M
Balance sheet
Cash & equivalents$45,000$19,000
Receivables$2,000$2,000
Current assets$51,000$25,000
PP&E, net$2,000$2,000
Total assets$53,000$27,000
Current liabilities$1.49M$769,000
Short-term debt—$41,000
Total liabilities$1.49M$769,000
Shareholders' equity-$1.43M-$742,000
Shares outstanding20.18M18.70M
Cash flow statement
Operating cash flow-$210,000-$532,000
Financing cash flow$236,000$321,000
Stock-based compensation$245,000$350,000

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.